Immune checkpoints consist of inhibitory and stimulatory pathways that maintain self-tolerance and assist with immune response. In cancer cells, immune checkpoint pathways are often activated to inhibit the nascent anti-tumor immune response. Immune checkpoint-blocking antibodies have come to the forefront of cancer immunotherapies as a powerful and promising strategy to activate the immune system.